Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease

Authors :: Tadashi Ikegami
Keizo Kato
Etsuko Iio
Hidenori Toyoda
Hiroshi Abe
Noritomo Shimada
Shigeru Mikami
Tomomi Okubo
Akihito Tsubota
Masanori Atsukawa
Norio Itokawa
Chisa Kondo
Taeang Arai
Takashi Kumada
Yoshimichi Chuganji
Yasushi Matsuzaki
Katsuhiko Iwakiri
Yasuhito Tanaka
Toru Asano
Source :: Hepatology Research. 48:549-555
Publication Year :: 2018
Publisher :: Wiley, 2018.
Abstract: AIM The aim of this study was to clarify the effects and safety of ombitasvir/paritaprevir/ritonavir (OBT/PTV/r) therapy in genotype 1b chronic hepatitis C patients with non-dialysis chronic kidney disease (CKD). METHODS This retrospective, multicenter study of 12-week OBT/PTV/r therapy included genotype 1b patients with non-dialysis CKD. Chronic kidney disease was defined as an estimated glomerular filtration rate (eGFR)

Full Text Access

Tools